| What to do | Strength of evidence |
|---|---|
| An institutional SCB test protocol is advised to ensure appropriate organisational aspects and standardisation. This includes minimum safety requirements, location, lead placement, and criteria for when to stop test. |  |
| It is advised that the testing location is always in-hospital and is adjusted in case of presumed higher risk for adverse events (e.g. testing in the cardiac catheterisation laboratory in the case of pre-existent AV conduction disturbances, presence of an SCN5A variant, etc.). | |
Minimum safety requirements for an SCB test include as follows:
| |
| It is advised that during the SCB test, ECG leads are recorded in higher right precordial positions (V1 and V2 in the second and/or third intercostal spaces). |  |
| Ajmaline is preferred over flecainide when available for SCB testing. | |
| During the SCB test, acquisition of ECGs is advised to be continuous, or at least every 30–60 s, and the test terminated when stopping criteria are met. | |
The criteria for stopping drug infusion during an SCB test are as follows:
| |
| What to do | Strength of evidence |
|---|---|
| An institutional SCB test protocol is advised to ensure appropriate organisational aspects and standardisation. This includes minimum safety requirements, location, lead placement, and criteria for when to stop test. | |
| It is advised that the testing location is always in-hospital and is adjusted in case of presumed higher risk for adverse events (e.g. testing in the cardiac catheterisation laboratory in the case of pre-existent AV conduction disturbances, presence of an SCN5A variant, etc.). | |
Minimum safety requirements for an SCB test include as follows:
| |
| It is advised that during the SCB test, ECG leads are recorded in higher right precordial positions (V1 and V2 in the second and/or third intercostal spaces). | |
| Ajmaline is preferred over flecainide when available for SCB testing. | |
| During the SCB test, acquisition of ECGs is advised to be continuous, or at least every 30–60 s, and the test terminated when stopping criteria are met. | |
The criteria for stopping drug infusion during an SCB test are as follows:
| |
| What to do | Strength of evidence |
|---|---|
| An institutional SCB test protocol is advised to ensure appropriate organisational aspects and standardisation. This includes minimum safety requirements, location, lead placement, and criteria for when to stop test. | |
| It is advised that the testing location is always in-hospital and is adjusted in case of presumed higher risk for adverse events (e.g. testing in the cardiac catheterisation laboratory in the case of pre-existent AV conduction disturbances, presence of an SCN5A variant, etc.). | |
Minimum safety requirements for an SCB test include as follows:
| |
| It is advised that during the SCB test, ECG leads are recorded in higher right precordial positions (V1 and V2 in the second and/or third intercostal spaces). | |
| Ajmaline is preferred over flecainide when available for SCB testing. | |
| During the SCB test, acquisition of ECGs is advised to be continuous, or at least every 30–60 s, and the test terminated when stopping criteria are met. | |
The criteria for stopping drug infusion during an SCB test are as follows:
| |
| What to do | Strength of evidence |
|---|---|
| An institutional SCB test protocol is advised to ensure appropriate organisational aspects and standardisation. This includes minimum safety requirements, location, lead placement, and criteria for when to stop test. | |
| It is advised that the testing location is always in-hospital and is adjusted in case of presumed higher risk for adverse events (e.g. testing in the cardiac catheterisation laboratory in the case of pre-existent AV conduction disturbances, presence of an SCN5A variant, etc.). | |
Minimum safety requirements for an SCB test include as follows:
| |
| It is advised that during the SCB test, ECG leads are recorded in higher right precordial positions (V1 and V2 in the second and/or third intercostal spaces). | |
| Ajmaline is preferred over flecainide when available for SCB testing. | |
| During the SCB test, acquisition of ECGs is advised to be continuous, or at least every 30–60 s, and the test terminated when stopping criteria are met. | |
The criteria for stopping drug infusion during an SCB test are as follows:
| |
